期刊
EUROPEAN CARDIOLOGY REVIEW
卷 14, 期 1, 页码 23-32出版社
RADCLIFFE CARDIOLOGY
DOI: 10.15420/ecr.2018.34.2
关键词
type 2 diabetes; heart failure; sodium-glucose cotransporter; sodium-glucose cotransporter inhibitors; cardiovascular outcome trials; safety profile
资金
- Instituto de Salud Carlos III [PI16/00398, CB16/11/00303]
- Comunidad de Madrid [B2017/BMD-3738]
Heart failure is a common complication in patients with diabetes, and people with both conditions present a worse prognosis. Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) increase urinary glucose excretion, improving glycaemic control. In type 2 diabetes (T2D), some SGLT2Is reduce major cardiovascular events, heart failure hospitalisations and worsening of kidney function independent of glycaemic control. Multiple mechanisms (haemodynamic, metabolic, hormonal and direct cardiac/renal effects) have been proposed to explain these cardiorenal benefits. SGLT2Is are generally well tolerated, but can produce rare serious adverse effects, and the benefit/risk ratio differs between SGLT2Is. This article analyses the mechanisms underlying the cardiorenal benefits and adverse effects of SGLT2Is in patients with T2D and heart failure and outlines some questions to be answered in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据